Immunodeficiency and intermittent dosing promote acquired rifamycin monoresistance in murine tuberculosis

Sang Won Park, Rokeya Tasneen, Paul J. Converse, Eric Nuermberger

Research output: Contribution to journalArticle

Abstract

More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the effects of immunodeficiency, intermittent dosing, and drug exposures, athymic nude and BALB/c mice were infected. Controls received daily rifapentine alone or 2 months of rifampin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampin/isoniazid, either daily or twice weekly with one of two isoniazid doses. Test groups received the same intensive regimen followed by once-weekly rifapentine or isoniazid/rifapentine with rifapentine doses of 10, 15, or 20 mg/kg of body weight plus one of two isoniazid doses. All combination regimens rendered BALB/c mouse cultures negative but selected mutants resistant to isoniazid (8.5%, 12/140) or rifampin (3.5%, 5/140) in nude mice (P 0.001). Intermittently dosed intensive-phase therapy selected isoniazid and rifampin resistance in 10% (8/80, P 0.001) and 20% (16/80, P 0.009) of nude mice, respectively, compared to 0% treated with a daily regimen. Once-weekly rifapentine-containing continuation-phase regimens selected rifampin-resistant mutants at a rate of 18.0% (18/100, P 0.035 compared to rifampin/isoniazid regimens). Higher isoniazid doses in the intermittent-treatment control regimen and higher rifapentine doses in once-weekly regimens were associated with less selection of isoniazid resistance. Acquired resistance, including rifamycin monoresistance, was more likely to occur in nude mice despite administration of combination therapy. These results recapitulate clinical outcomes and indicate that nude mice may be useful for evaluating the ability of novel regimens to prevent the selection of resistance.

Original languageEnglish (US)
Article numbere01502-17
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

rifapentine
Isoniazid
Tuberculosis
Rifampin
Nude Mice
rifamycin SV
Pyrazinamide
Ethambutol
Pharmaceutical Preparations
Body Weight

Keywords

  • Acquired rifamycin resistance
  • Immunodeficiency
  • Intermittent therapy
  • Nude mouse
  • Tuberculosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Immunodeficiency and intermittent dosing promote acquired rifamycin monoresistance in murine tuberculosis. / Park, Sang Won; Tasneen, Rokeya; Converse, Paul J.; Nuermberger, Eric.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 11, e01502-17, 01.11.2017.

Research output: Contribution to journalArticle

@article{95991c12f23142ed8b90b07c48bcdbf1,
title = "Immunodeficiency and intermittent dosing promote acquired rifamycin monoresistance in murine tuberculosis",
abstract = "More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the effects of immunodeficiency, intermittent dosing, and drug exposures, athymic nude and BALB/c mice were infected. Controls received daily rifapentine alone or 2 months of rifampin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampin/isoniazid, either daily or twice weekly with one of two isoniazid doses. Test groups received the same intensive regimen followed by once-weekly rifapentine or isoniazid/rifapentine with rifapentine doses of 10, 15, or 20 mg/kg of body weight plus one of two isoniazid doses. All combination regimens rendered BALB/c mouse cultures negative but selected mutants resistant to isoniazid (8.5{\%}, 12/140) or rifampin (3.5{\%}, 5/140) in nude mice (P 0.001). Intermittently dosed intensive-phase therapy selected isoniazid and rifampin resistance in 10{\%} (8/80, P 0.001) and 20{\%} (16/80, P 0.009) of nude mice, respectively, compared to 0{\%} treated with a daily regimen. Once-weekly rifapentine-containing continuation-phase regimens selected rifampin-resistant mutants at a rate of 18.0{\%} (18/100, P 0.035 compared to rifampin/isoniazid regimens). Higher isoniazid doses in the intermittent-treatment control regimen and higher rifapentine doses in once-weekly regimens were associated with less selection of isoniazid resistance. Acquired resistance, including rifamycin monoresistance, was more likely to occur in nude mice despite administration of combination therapy. These results recapitulate clinical outcomes and indicate that nude mice may be useful for evaluating the ability of novel regimens to prevent the selection of resistance.",
keywords = "Acquired rifamycin resistance, Immunodeficiency, Intermittent therapy, Nude mouse, Tuberculosis",
author = "Park, {Sang Won} and Rokeya Tasneen and Converse, {Paul J.} and Eric Nuermberger",
year = "2017",
month = "11",
day = "1",
doi = "10.1128/AAC.01502-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Immunodeficiency and intermittent dosing promote acquired rifamycin monoresistance in murine tuberculosis

AU - Park, Sang Won

AU - Tasneen, Rokeya

AU - Converse, Paul J.

AU - Nuermberger, Eric

PY - 2017/11/1

Y1 - 2017/11/1

N2 - More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the effects of immunodeficiency, intermittent dosing, and drug exposures, athymic nude and BALB/c mice were infected. Controls received daily rifapentine alone or 2 months of rifampin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampin/isoniazid, either daily or twice weekly with one of two isoniazid doses. Test groups received the same intensive regimen followed by once-weekly rifapentine or isoniazid/rifapentine with rifapentine doses of 10, 15, or 20 mg/kg of body weight plus one of two isoniazid doses. All combination regimens rendered BALB/c mouse cultures negative but selected mutants resistant to isoniazid (8.5%, 12/140) or rifampin (3.5%, 5/140) in nude mice (P 0.001). Intermittently dosed intensive-phase therapy selected isoniazid and rifampin resistance in 10% (8/80, P 0.001) and 20% (16/80, P 0.009) of nude mice, respectively, compared to 0% treated with a daily regimen. Once-weekly rifapentine-containing continuation-phase regimens selected rifampin-resistant mutants at a rate of 18.0% (18/100, P 0.035 compared to rifampin/isoniazid regimens). Higher isoniazid doses in the intermittent-treatment control regimen and higher rifapentine doses in once-weekly regimens were associated with less selection of isoniazid resistance. Acquired resistance, including rifamycin monoresistance, was more likely to occur in nude mice despite administration of combination therapy. These results recapitulate clinical outcomes and indicate that nude mice may be useful for evaluating the ability of novel regimens to prevent the selection of resistance.

AB - More-permissive preclinical models may be useful in evaluating antituberculosis regimens for their propensity to select drug-resistant mutants. To evaluate whether acquired rifamycin monoresistance could be recapitulated in mice and, if so, to evaluate the effects of immunodeficiency, intermittent dosing, and drug exposures, athymic nude and BALB/c mice were infected. Controls received daily rifapentine alone or 2 months of rifampin, isoniazid, pyrazinamide, and ethambutol, followed by 4 months of rifampin/isoniazid, either daily or twice weekly with one of two isoniazid doses. Test groups received the same intensive regimen followed by once-weekly rifapentine or isoniazid/rifapentine with rifapentine doses of 10, 15, or 20 mg/kg of body weight plus one of two isoniazid doses. All combination regimens rendered BALB/c mouse cultures negative but selected mutants resistant to isoniazid (8.5%, 12/140) or rifampin (3.5%, 5/140) in nude mice (P 0.001). Intermittently dosed intensive-phase therapy selected isoniazid and rifampin resistance in 10% (8/80, P 0.001) and 20% (16/80, P 0.009) of nude mice, respectively, compared to 0% treated with a daily regimen. Once-weekly rifapentine-containing continuation-phase regimens selected rifampin-resistant mutants at a rate of 18.0% (18/100, P 0.035 compared to rifampin/isoniazid regimens). Higher isoniazid doses in the intermittent-treatment control regimen and higher rifapentine doses in once-weekly regimens were associated with less selection of isoniazid resistance. Acquired resistance, including rifamycin monoresistance, was more likely to occur in nude mice despite administration of combination therapy. These results recapitulate clinical outcomes and indicate that nude mice may be useful for evaluating the ability of novel regimens to prevent the selection of resistance.

KW - Acquired rifamycin resistance

KW - Immunodeficiency

KW - Intermittent therapy

KW - Nude mouse

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85032487910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032487910&partnerID=8YFLogxK

U2 - 10.1128/AAC.01502-17

DO - 10.1128/AAC.01502-17

M3 - Article

C2 - 28874368

AN - SCOPUS:85032487910

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

M1 - e01502-17

ER -